MGI, SuperGen submit Dacogen MAA

MOGN and SUPG submitted an MAA to the EMEA for Dacogen decitabine to treat myelodysplastic syndromes (MDS). In the U.S., the companies expect to complete a rolling NDA submission for the hypomethylati...